TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15114907

Group type: EXPERIMENTAL
Intervention: Two types of judgment combined with two stimulus dimensions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of two types of judgment with two stimulus dimensions
Number of subjects: 0
Study: 11557191

Group type: EXPERIMENTAL
Intervention: Pyridoxine (100 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Folate (5 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 9590462

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg taken orally once daily for 7 consecutive days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Irbesartan administration on day 1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Irbesartan administration on day 7
Number of subjects: 20
Study: 7599468

Group type: EXPERIMENTAL
Intervention: Normal saline (experimental group)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Heparinised saline (control group)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Use of i.v. antibiotics tobramycin
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Use of i.v. antibiotics Timentin
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Flushing solution (both normal saline and heparinised saline)
Number of subjects: 152
Study: 3279997

Group type: EXPERIMENTAL
Intervention: Maintenance melphalan and prednisone (MP)
Number of subjects: 185

Group type: COMPARATOR
Intervention: No maintenance treatment (stopping MP)
Number of subjects: 185
Study: 28069992

Group type: EXPERIMENTAL
Intervention: Structured education programme
Number of subjects: 706

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 706
Study: 27999850

Group type: COMPARATOR
Intervention: Placebo (Lecithin, 2400 mg daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (eicosapentaenoic acid (EPA); 1770 mg, and docosahexaenoic acid (DHA); 390 mg, daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vitamin D (1,000 IU daily)
Number of subjects: 24
Study: 25574715

Group type: EXPERIMENTAL
Intervention: 50% Acacia nilotica
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine (active control)
Number of subjects: 90

Group type: COMPARATOR
Intervention: saline water (passive control)
Number of subjects: 90
Study: 23791619

Group type: EXPERIMENTAL
Intervention: 30 mg MK-7123
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 20009942

Group type: EXPERIMENTAL
Intervention: In vivo refractometry using lotrafilcon B lens
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: In vivo refractometry using etafilcon A lens
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ex vivo refractometry using lotrafilcon B lens
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ex vivo refractometry using etafilcon A lens
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Statistical significance for etafilcon A lens
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Statistical significance for lotrafilcon B lens
Number of subjects: 9
Study: 18198223

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverages
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Protein beverages
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lipid beverages
Number of subjects: 16
Study: 16169314

Group type: EXPERIMENTAL
Intervention: Clopidogrel in addition to low- to moderate-dose aspirin
Number of subjects: 15603

Group type: COMPARATOR
Intervention: Placebo in addition to low- to moderate-dose aspirin
Number of subjects: 15603
Study: 14582907

Group type: EXPERIMENTAL
Intervention: Short-burst oxygen therapy (SBOT) before exercise
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Short-burst oxygen therapy (SBOT) after exercise
Number of subjects: 22

Group type: COMPARATOR
Intervention: Air (control) before exercise
Number of subjects: 22

Group type: COMPARATOR
Intervention: Air (control) after exercise
Number of subjects: 22
Study: 10577444

Group type: EXPERIMENTAL
Intervention: Titration of ACE inhibitor dosage according to serial measurement of plasma BNP concentration (BNP group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Optimal empirical ACE inhibitor therapy (clinical group)
Number of subjects: 20
Study: 8735314

Group type: EXPERIMENTAL
Intervention: Contraceptive pill
Number of subjects: 5
Study: 1753161

Group type: EXPERIMENTAL
Intervention: Symptom limited exercise test (ET) performed before discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptom limited exercise test (ET) performed after one month
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both ETs (before discharge and after one month)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptom limited ET performed before discharge
Number of subjects: 0
Study: 7459218

Group type: EXPERIMENTAL
Intervention: Good-prognosis group (BUC <= 8 mM, [Hb] >= 100 g/l, no or minimal symptoms)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Intermediate prognosis group (combinations of determinant features excluding good and poor prognosis)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Poor-prognosis group ([Hb] <= 75 g/l or BUC > 10 mM and restricted clinical activity)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Overall survival probabilities for prognostic groups
Number of subjects: 485
Study: 31108814

Group type: EXPERIMENTAL
Intervention: Synthesized oligopeptides; specific peptides synthesized for confirmation and quantification; details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proteinase cleavage site analysis; no specific intervention mentioned.
Number of subjects: 0
Study: 27796575

Group type: EXPERIMENTAL
Intervention: Powered Toothbrush (PT)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Manual Toothbrush (MT)
Number of subjects: 110
Study: 25870998

Group type: EXPERIMENTAL
Intervention: Monopolar energy (Group 1)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Bipolar energy (Group 2)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Monopolar energy (Group 1) among CP patients
Number of subjects: 124

Group type: COMPARATOR
Intervention: Bipolar energy (Group 2) among CP patients
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Monopolar energy (Group 1) among BPH patients
Number of subjects: 124

Group type: COMPARATOR
Intervention: Bipolar energy (Group 2) among BPH patients
Number of subjects: 124
Study: 23478479

Group type: EXPERIMENTAL
Intervention: Vibration and Stretching (VS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vibration Only (VO)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Stretching Only (SO)
Number of subjects: 21
Study: 21168981

Group type: EXPERIMENTAL
Intervention: Chronic disease management (CDM) care
Number of subjects: 282
Study: 19185687

Group type: EXPERIMENTAL
Intervention: EUS-guided CBD stone removal
Number of subjects: 52

Group type: COMPARATOR
Intervention: ERCP-guided CBD stone removal
Number of subjects: 52
Study: 16393735

Group type: EXPERIMENTAL
Intervention: Naltrexone (25/50 mg dd.) combined with nicotine replacement therapy (NRT) and Community Reinforcement Approach (CRA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-psychosocial therapy group
Number of subjects: 25
Study: 15289705

Group type: EXPERIMENTAL
Intervention: Lormetazepam 0.03 mg/kg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lormetazepam at 20.00 h
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lormetazepam at 22.00 h
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lormetazepam at 18.00 h
Number of subjects: 38
Study: 11397963

Group type: EXPERIMENTAL
Intervention: Daclizumab (5 doses at biweekly intervals), 3 gm/day mycophenolate mofetil for the first 6 months and 2 gm thereafter, conventional corticosteroid therapy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Daclizumab, mycophenolate mofetil, corticosteroids
Number of subjects: 98

Group type: COMPARATOR
Intervention: CNI use (more than 7 days)
Number of subjects: 98

Group type: COMPARATOR
Intervention: No CNI use
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: CNI avoidance regimen
Number of subjects: 98
Study: 9431900

Group type: EXPERIMENTAL
Intervention: Amoxycillin 750 mg t.i.d. and Metronidazole 500 mg t.i.d. for 12 days with Famotidine 40 mg for 6 weeks
Number of subjects: 129

Group type: COMPARATOR
Intervention: Amoxycillin 1000 mg b.i.d. and Metronidazole 500 mg b.i.d. for 12 days with Famotidine 40 mg for 6 weeks
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Amoxycillin 750 mg t.i.d. and Metronidazole 500 mg t.i.d. for 12 days
Number of subjects: 129

Group type: COMPARATOR
Intervention: Amoxycillin 1000 mg b.i.d. and Metronidazole 500 mg b.i.d. for 12 days
Number of subjects: 129
Study: 7904930

Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective beta-blocker with no ISA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pindolol (non-selective blocker with ISA)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-1-selective blocker with ISA)
Number of subjects: 21
Study: 3551493

Group type: EXPERIMENTAL
Intervention: Pancrease (pH-sensitive enteric-coated microspheres)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Pancreatin (conventional enteric-coated granules)
Number of subjects: 11
Study: 29388815

Group type: EXPERIMENTAL
Intervention: Selepressin (various dosing strategies)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1800
Study: 27008245

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 14
Study: 24333157

Group type: EXPERIMENTAL
Intervention: Integrated medical care management and behavioral risk factor reduction
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study: 23394506

Group type: EXPERIMENTAL
Intervention: New epinephrine autoinjector
Number of subjects: 180

Group type: COMPARATOR
Intervention: Old epinephrine autoinjector
Number of subjects: 180
Study: 20588151

Group type: EXPERIMENTAL
Intervention: IV lidocaine (1 mg/min for patients < 70 kg, 2 mg/min for patients ≥ 70 kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Epidural bupivacaine (0.125% and hydromorphone 6 microg/mL at 10 mL/hr)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: IV lidocaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Epidural bupivacaine
Number of subjects: 42
Study: 16903880

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets (ITN)
Number of subjects: 10726

Group type: COMPARATOR
Intervention: Control (no net provision)
Number of subjects: 10726
Study: 14994886

Group type: EXPERIMENTAL
Intervention: 0.014 inch archwire
Number of subjects: 109

Group type: COMPARATOR
Intervention: 0.016 inch archwire
Number of subjects: 109
Study: 11708707

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.1 g x kg(‐1) lean body mass)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 40
Study: 9481973

Group type: EXPERIMENTAL
Intervention: 100% supplemental oxygen (O2)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 50% nitrous oxide (N2O) and 50% O2
Number of subjects: 46
Study: 7957514

Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg every 12 h for three consecutive days
Number of subjects: 5

Group type: COMPARATOR
Intervention: Enoxacin 200 mg every 8 h for three consecutive days
Number of subjects: 5
Study: 3596867

Group type: EXPERIMENTAL
Intervention: Sustained release tiaprofenic acid 600 mg once daily
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Conventional tablet tiaprofenic acid 300 mg twice daily
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 28256305

Group type: EXPERIMENTAL
Intervention: KinesioTape with tension
Number of subjects: 30

Group type: COMPARATOR
Intervention: KinesioTape without tension (placebo)
Number of subjects: 30
Study: 27306909

Group type: EXPERIMENTAL
Intervention: SurvivorCare (SC)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 221
Study: 24594542

Group type: EXPERIMENTAL
Intervention: Dornase alfa
Number of subjects: 23

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 23
Study: 22782384

Group type: EXPERIMENTAL
Intervention: Traditional resistance exercise for the lower extremity (EG)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Traditional group (TG)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Power group (PG)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Rapid strength group (RG)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Rapid strength group (RG) and Power group (PG)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 58
Study: 20169461

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g/day for 6 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVC) 0.5-1 g/m2 monthly for 6 months
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both MMF and IVC
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: MMF
Number of subjects: 47
Study: 18205656

Group type: EXPERIMENTAL
Intervention: Professional oral care (POC) by a dental hygienist
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tooth brushing and mouth rinsing by patients themselves according to the instructions of a nurse (control)
Number of subjects: 40
Study: 16169891

Group type: EXPERIMENTAL
Intervention: Lidocaine 30 mg and propofol 2.5 mg kg(‐1) (Group 1)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg kg(‐1) (Group 2)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Lidocaine 30 mg and thiopental 5 mg kg(‐1) (Group 3)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg kg(‐1) (Group 4)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Lidocaine 30 mg and etomidate 0.3 mg kg(‐1) (Group 5)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Mean apnoea time in Group 1
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Mean apnoea time in Group 2
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Mean apnoea time in Group 3
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Mean apnoea time in Group 4
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Mean apnoea time in Group 5
Number of subjects: 175
Study: 15321934

Group type: EXPERIMENTAL
Intervention: BIS, SE, RE during propofol infusion with remifentanil (Ce(REMI) 0, 2 or 4 ng ml(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: BIS, SE, RE during propofol infusion without remifentanil (Ce(REMI) 0 ng ml(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BIS, SE, RE
Number of subjects: 60
Study: 11377152

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1% to 8%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Halothane (0.5% to 5%)
Number of subjects: 60
Study: 9218012

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 7967863

Group type: EXPERIMENTAL
Intervention: Blood samples obtained via central venous catheter (CVC)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Blood samples obtained via venipuncture
Number of subjects: 250
Study: 3671893

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) in fasting state
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) with a protein-fat-rich breakfast
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) at 8 a.m.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of 800 mg of the ultrasustained-release theophylline preparation (Theo-1) at 8 p.m.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dosing of 400, 800, and 1,200 mg of the ultrasustained-release theophylline preparation (Theo-1) for 3 days each in steady state
Number of subjects: 37
Study: 29016481

Group type: EXPERIMENTAL
Intervention: Auto-regulatory exercise selection (AES)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Fixed exercise selection (FES)
Number of subjects: 17
Study: 29373987

Group type: EXPERIMENTAL
Intervention: COMPASS model (integrates early supported discharge planning with transitional care management, including nurse-led follow-up phone calls after 2, 30, and 60 days and an in-person clinic visit at 7-14 days)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 95
Study: 27088487

Group type: EXPERIMENTAL
Intervention: Volume Guarantee (VG) ventilation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pressure Control (PC) ventilation
Number of subjects: 24
Study: 25907082

Group type: EXPERIMENTAL
Intervention: Routine final kissing balloon
Number of subjects: 725

Group type: COMPARATOR
Intervention: Leave-alone
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Crush
Number of subjects: 725

Group type: COMPARATOR
Intervention: Single-stent
Number of subjects: 725
Study: 23748515

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Number of subjects: 1681

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1681
Study: 20563833

Group type: EXPERIMENTAL
Intervention: Convection enhanced delivery (CED) of IL13‐PE38QQR
Number of subjects: 180

Group type: COMPARATOR
Intervention: Gliadel Wafers (GW)
Number of subjects: 180
Study: 17936910

Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 1113
Study: 17012691

Group type: EXPERIMENTAL
Intervention: 10-week group cognitive behavior stress management intervention
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 199
Study: 12594664

Group type: EXPERIMENTAL
Intervention: Argon beam coagulation (ABC) applied to the cut surface of the hepatic ligaments and bare area of the retroperitoneum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no ABC applied)
Number of subjects: 60
Study: 10737446

Group type: EXPERIMENTAL
Intervention: Nonspecific guideline
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Specific guideline
Number of subjects: 900

Group type: COMPARATOR
Intervention: No guideline
Number of subjects: 900
Study: 8959115

Group type: EXPERIMENTAL
Intervention: Filgrastim as an adjunct to antibiotics for the treatment of CAP
Number of subjects: 100

Group type: COMPARATOR
Intervention: APACHE II classification system for severity of disease
Number of subjects: 100
Study: 1307994

Group type: EXPERIMENTAL
Intervention: 30 nopal capsules
Number of subjects: 20

Group type: COMPARATOR
Intervention: 30 placebo capsules
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 nopal capsules t.i.d. for one week
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 placebo capsules t.i.d. for one week
Number of subjects: 20
Study: 6698666

Group type: EXPERIMENTAL
Intervention: naproxen sodium suppositories (equivalent to 500 mg naproxen)
Number of subjects: 11

Group type: COMPARATOR
Intervention: naproxen suppositories (500 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: naproxen sodium suppositories
Number of subjects: 11

Group type: COMPARATOR
Intervention: naproxen suppositories
Number of subjects: 11
Study: 31204437

Group type: EXPERIMENTAL
Intervention: Icon® resin infiltration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clinpro™ XT varnish
Number of subjects: 12
Study: 28982882

Group type: EXPERIMENTAL
Intervention: Vinorelbine and Gemcitabine (NG)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Vinorelbine and Cisplatin (NP)
Number of subjects: 74
Study: 25794045

Group type: EXPERIMENTAL
Intervention: Bedaquiline plus background regimen (BBR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Background regimen (BR)
Number of subjects: 0
Study: 23939169

Group type: EXPERIMENTAL
Intervention: Diode laser (Di group)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Thulium laser (Thu group)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study: 21866498

Group type: EXPERIMENTAL
Intervention: Step-count goal setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monitoring step counts with pedometers (Control)
Number of subjects: 0
Study: 19621729

Group type: EXPERIMENTAL
Intervention: Postprandial 190 mL black coffee
Number of subjects: 6

Group type: COMPARATOR
Intervention: Test meal alone
Number of subjects: 6
Study: 16792761

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) treatment (585 nm)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Calcipotriol/betamethasone dipropionate (Dovobet) treatment
Number of subjects: 8
Study: 14971969

Group type: EXPERIMENTAL
Intervention: Complex group (complex exercises)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Isolated group (2-kg dumbbells)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 39
Study: 11165422

Group type: EXPERIMENTAL
Intervention: Interleukin-2
Number of subjects: 0
Study: 9412795

Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg i.m. at 4-week intervals for 3 months)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Leuprolide (3.75 mg s.c. at 4-week intervals for 3 months)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg i.m.)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Leuprolide (3.75 mg s.c.)
Number of subjects: 67
Study: 7693419

Group type: EXPERIMENTAL
Intervention: Anthracycline-containing regimen given at the earliest possible time interval after surgery
Number of subjects: 2795

Group type: COMPARATOR
Intervention: Chemotherapy started 12 weeks before surgery
Number of subjects: 2795

Group type: COMPARATOR
Intervention: Therapy initiated shortly (perioperatively) after surgery
Number of subjects: 2795
Study: 2892430

Group type: EXPERIMENTAL
Intervention: Premedication with lormetazepam (2 mg evening prior, 1 mg 2 hours prior) and propofol (2.4 mg/kg) with 70% nitrous oxide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol (2.4 mg/kg) with 70% nitrous oxide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Additional i.v. injection of fentanyl (3 micrograms/kg) prior to propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: No premedication with lormetazepam and propofol (2.4 mg/kg) with 70% nitrous oxide
Number of subjects: 40